The Masonic Cancer Center creates a collaborative research environment focused on the causes, prevention, detection, and treatment of cancer; applying that knowledge to improve quality of life for patients and survivors; and sharing its discoveries with other scientists, students, professionals, and the community.
Read the 2016 Annual Report
Chainbreaker is an exciting fundraising experience that includes a weekend of cycling, entertainment, and volunteerism. 100% of the funds raised by riders goes to fund life-saving cancer research at the Masonic Cancer Center, University of Minnesota. More information and to register
The Masonic Cancer Center's clinical partner is University of Minnesota Health. Visit mhealth.org/cancer to find information about cancer care, providers and cancer clinic locations.
Cancer Information Nurse Line
Reach a nurse specializing in cancer care, Monday through Friday from 8 a.m. to 4:30 p.m.
New cancer treatments must prove to be safe and effective in scientific studies with a certain number of patients before they can be made widely available. Through clinical trials, researchers learn which approaches are more effective than others.
Our Research Focus
The Masonic Cancer Center brings together scientists from different disciplines to discover processes that affect cancer. It is home to state-of-the-art research tools and some of the world's top cancer researchers in:
MINNEAPOLIS/ST. PAUL (February 28, 2017) – Survivors of childhood cancers have fewer secondary cancers, according to new research from the Masonic Cancer Center, University of Minnesota and St. Jude Children’s Research Hospital. Compared with those diagnosed in the 1970s, patients diagnosed after 1990 are experiencing better outcomes. Researchers believe the difference comes from a reduction in exposure to therapeutic radiation.
MINNEAPOLIS/ST.PAUL (February 13, 2017) – A breakthrough trial at the University of Minnesota testing a new UMN-developed drug resulted in improved survival rates for dogs diagnosed with a cancer called hemangiosarcoma (HSA). The results were published today in the journal Molecular Cancer Therapeutics.
Masonic Cancer Center, founded in 1991, is a National Cancer Institute Comprehensive Cancer Center, one of only 47 institutions in the United States and two in Minnesota to hold that designation.
A state-of-the-art facility with 52,000 square feet of laboratory space, which expands the opportunities for collaborative research at the Masonic Cancer Center. It's the gateway to the Biomedical Discovery District.